Biotech Values

[Praveen]

would you prefer nivo plus chemo combo arm over nivo plus yervoy.
On ALK,(reposted from SI) There is a pfizer trial going to enroll soon supposed to cross bbb unlike xalkori. It showed in cell assays that it potently inhibited the activity of ALK and all eight of the mutant forms of ALK known to cause resistance to crizotinib in patients with lung cancer. They showed that PF-06463922 inhibited the growth of tumors harboring three of the crizotinib-resistant ALK mutants, including the most resistant ALK mutant, G1202R, in mice. Since it is so early maybe we can't compare it with ap26113
http://clinicaltrials.gov/ct2/show/NCT01970865?term=pf06463922&rank=1